Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:13 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations
NCT03139032 · Arena Pharmaceuticals · PHASE2 · terminated · last registry update 2020-12-31 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision to terminate the study” | – | Registry record, Arena Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against S1PR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-11-26Results posted on the registry: Arena Pharmaceuticals, Etrasimod + Placebo (NCT02536404)
- 2021-11-17Phase 3 first posted: Hoffmann-La Roche, Ocrelizumab + Fingolimod (NCT05123703)
- 2021-10-13Phase 3 first posted: Bristol-Myers Squibb, Ozanimod (NCT05076175)
- 2021-09-01Results posted on the registry: Celgene, RPC1063 + Placebo (NCT02435992)
- 2021-08-31Phase 3 first posted: Celgene, Tetanus, diphtheria, and acellular pertussis vaccine + Pneumococcal polysaccharide vaccine (NCT05028634)
- 2021-07-29Also stopped (terminated): Charite University, Berlin, Germany, Verum arm receiving Gilenya® + Active Comparator receiving Extavia® (NCT01647880)
- 2021-07-22Also stopped (withdrawn): Second Affiliated Hospital, Zhejiang University, School of Medicine, Fingolimod (NCT02956200)
- 2021-06-15Phase 3 first posted: Novartis Pharmaceuticals, Fingolimod + Ofatumumab (NCT04926818)
- 2021-06-14Phase 3 first posted: State University of New York at Buffalo, Mayzent + Ocrevus (NCT04925557)
- 2021-06-11Results posted on the registry: Actelion, ponesimod + teriflunomide (NCT02425644)
- 2021-06-11Results posted on the registry: Actelion, ACT-128800 Dose 1 + Placebo (NCT01006265)
- 2021-06-11Results posted on the registry: Arena Pharmaceuticals, APD334 (NCT03072953)
- 2021-06-11Also stopped (terminated): Arena Pharmaceuticals, APD334 (NCT03072953)
- 2021-06-07Results posted on the registry: Novartis Pharmaceuticals, BAF312 solution + Matching Placebo for BAF312 solution (NCT03338998)
- 2021-05-18Results posted on the registry: Actelion, Ponesimod (NCT02907177)
- 2021-05-18Also stopped (terminated): Actelion, Ponesimod (NCT02907177)
- 2021-04-05Results posted on the registry: Arena Pharmaceuticals, Etrasimod + Placebo (NCT02447302)
- 2021-02-11Results posted on the registry: Celgene, Ozanimod + Ozanimod placebo (NCT02047734)
- 2021-02-11Results posted on the registry: Celgene, Ozanimod + Placebo (NCT01628393)
- 2021-02-10Results posted on the registry: Novartis Pharmaceuticals, Fingolimod (NCT02232061)
- 2021-01-13Phase 3 first posted: Pfizer, Etrasimod + Placebo (NCT04706793)
- 2021-01-05Also stopped (terminated): Novartis Pharmaceuticals, BAF312 + Placebo (NCT02029274)
- 2021-01-05Also stopped (terminated): Novartis Pharmaceuticals, Placebo + BAF312 (NCT01801917)
- 2020-11-25Results posted on the registry: Celgene, Ozanimod + Interferon beta-1a (NCT02294058)
- 2020-11-13Also stopped (withdrawn): First Affiliated Hospital of Fujian Medical University, Fingolimod 0.5 mg (NCT04280588)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision